Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: A randomized placebo-controlled crossover study

Diabetic Medicine

Volumn 29, Issue 8, 2012, Pages

  Nielsen, S E ^a   Persson, F ^a   Frandsen, E ^a   Sugaya, T ^a   Hess, G ^a   Zdunek, D ^a   Shjoedt, K J ^a   Parving, H H ^a   Rossing, P ^a  

^a STENO DIABETES CENTER   (Denmark)

Author keywords

Diabetic nephropathy; Renin angiotensin aldosterone system (RAAS) blockade; Urinary albumin excretion

Indexed keywords

ALBUMIN; FATTY ACID BINDING PROTEIN; KIDNEY INJURY MOLECULE 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; POTASSIUM; SPIRONOLACTONE; UNCLASSIFIED DRUG; URINARY LIVER TYPE FATTY ACID BINDING PROTEIN;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIURETIC THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY TUBULE DAMAGE; MALE; MICROALBUMINURIA; NAUSEA; POTASSIUM BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; URINARY EXCRETION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALBUMINURIA; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DIURETICS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MIDDLE AGED; SPIRONOLACTONE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84864023693     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2012.03585.x     Document Type: Article

References (27)

1. Parving H-H, Mauer M, Ritz E. Diabetic Nephropathy. In Brenner BM, ed. Brenner & Rector's The Kidney, 8th edn. Boston: WB Saunders, 2008; 1265-1298.
2. Kelly DJ, Cox AJ, Tolcos M, Cooper ME, Wilkinson-Berka JL, Gilbert RE. Attenuation of tubular apoptosis by blockade of the renin--angiotensin system in diabetic Ren-2 rats. Kidney Int 2002; 61: 31-39.
3. Marre M, Chatellier G, Leblanc H, Guyenne T-T, Ménard J, Passa Ph. Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. Br Med J 1988; 297: 1092-1095.
4. Mathiesen ER, Hommel E, Hansen HP, Smidt UM, Parving HH. Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria. Br Med J 1999; 319: 24-25.
5. Gurley SB, Coffman TM. The renin-angiotensin system and diabetic nephropathy. Semin Nephrol 2007; 27: 144-152.
6. Schrier RW, Masoumi A, Elhassan E. Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome. Clin J Am Soc Nephrol 2010; 5: 1132-1140.
7. Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Rossing P, Tarnow L et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 2005; 68: 2829-2836.
8. Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving H-H. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care 2005; 28: 2106-2112.
9. Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2009; 4: 542-551.
10. Kamijo A, Sugaya T, Hikawa A, Okada M, Okumura F, Yamanouchi M et al. Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules. Am J Pathol 2004; 165: 1243-1255.
11. Cowland JB, Sorensen OE, Sehested M, Borregaard N. Neutrophil gelatinase-associated lipocalin is up-regulated in human epithelial cells by IL-1 beta, but not by TNF-alpha. J Immunol 2003; 171: 6630-6639.
12. van Timmeren MM, van den Heuvel MC, Bailly V, Bakker SJ, Van GH, Stegeman CA. Tubular kidney injury molecule-1 (KIM-1) in human renal disease. J Pathol 2007; 212: 209-217.
13. Nielsen SE, Schjoedt KJ, Astrup AS, Tarnow L, Lajer M, Hansen PR et al. Neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule 1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril. Diabet Med 2010; 27: 1144-1150.
14. Nielsen SE, Sugaya T, Hovind P, Baba T, Parving HH, Rossing P. Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patients. Diabetes Care 2010; 33: 1320-1324.
15. Sibbald B, Roberts C. Understanding controlled trials. Crossover trials. Br Med J 1998; 316: 1719.
16. Bröchner-Mortensen J, Rödbro P. Selection of routine method for determination of glomerular filtration rate in adult patients. Scand J Clin Lab Invest 1976; 36: 35-45.
17. Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Tarnow L, Rossing P et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int 2006; 70: 536-542.
18. de Zeeuw D, Remuzzi G, Parving H-H, Keane WF, Zhang Z, Shahinfar S et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004; 65: 2309-2320.
19. Messerli FH. The sudden demise of dual renin-angiotensin system blockade or the soft science of the surrogate end point. J Am Coll Cardiol 2009; 53: 468-470.
20. Schmieder RE, Mann JF, Schumacher H, Gao P, Mancia G, Weber MA et al. Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol 2011; 22: 1353-1364.
21. Mathiesen ER, Feldt-Rasmussen B, Hommel E, Deckert T, Parving H-H. Stable glomerular filtration rate in normotensive IDDM patients with stable microalbuminuria. Diabetes Care 1997; 20: 286-289.
22. Apperloo AJ, de Zeeuw D, van Essen G, de Jong PE. The initial GFR decline on antihypertensive treatment in long-term intervention studies is reversible after withdrawal of treatment. J Am Soc Nephrol 1994; 5: 324.
23. Epstein M. Aldosterone as a mediator of progressive renal dysfunction: evolving perspectives. Intern Med 2001; 40: 573-583.
24. Epstein M. Aldosterone as a determinant of cardiovascular and renal dysfunction. J R Soc Med 2001; 94: 378-383.
25. Sato A, Hayashi K, Saruta T. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 2005; 18: 44-49.
26. Tylicki L, Rutkowski P, Renke M, Larczynski W, Aleksandrowicz E, Lysiak-Szydlowska W et al. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. Am J Kidney Dis 2008; 52: 486-493.
27. Nielsen SE, Sugaya T, Tarnow L, Lajer M, Schjoedt KJ, Astrup AS et al. Tubular and glomerular injury in diabetes and the impact of ACE inhibition. Diabetes Care 2009; 32: 1684-1688.